Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Duramed Verapamil Production Resumption Expected Within Several Months

Executive Summary

Duramed plans to resume manufacturing of the hypertension drug verapamil at its Somerset, N.J. plant in the next few months.

You may also be interested in...



Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake

Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.

Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake

Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.

Medicare Rx Benefit "More Significant" Than Waxman/Hatch Reform - Barr

Enactment of a Medicare prescription drug benefit is a higher priority for generic drug companies than reforms to the Waxman/Hatch Act, Barr CEO Bruce Downey told analysts Aug. 7.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel